Skip to main content
Caplight Logo









illumicell AI

illumicell AI

Private
United StatesHealthcare & Life Scienceshttps://www.illumicell.ai/

Last Round

VC Round

Jun 19, 2026

Total Funding Raised

$2M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

illumicell AI is a healthcare technology company that provides a portable AI-powered platform for real-time, fluid-based cellular diagnostics, with an initial focus on male fertility.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Medical AI, Drug Discovery, Healthcare Analytics

Business Model

B2B

Customer Profile

Hardware + Subscription, Data as a Service

AI Layer

Application

Keywords

drug discoverymedical AIAI-native diagnosticscellular analysisdeep learning segmentationbiotechdigital biobankhigh-content imagingpoint-of-care diagnosticscomputational biologyfertility techlab scannerbiomarker discoverySaaSlab-on-a-chip

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

illumicell AI Comparables

Compare illumicell AI with similar companies based on industry and business-model similarity.

illumicell AI comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Valo Health
72%
Labcorp
67%
Insilico Medicine
67%

illumicell AI Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
VC RoundJun 19, 2026
Pre SeedApr 10, 2025

Key People

Founding team and executive leadership

Loup Cordey

CTO And Co-founder Of Illumicell.ai

Founding Team

Michel Bielecki

Co-Founder CEO

Founding Team

Trevor Slattery

Chief Technology Officer

Executive Team

illumicell AI Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Aug 22, 2026

    Grew 40% QoQ, from 15 to 21 employees.

  • Aug 1, 2026

    Grew 33% QoQ from 15 to 20 employees.

illumicell AI Filings

Explore SEC and related filing metadata, where available.

illumicell AI filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about illumicell AI's valuation, stock price, and market status.

Is illumicell AI a public or private company?

illumicell AI is a private company.

What is the current stock price of illumicell AI?

illumicell AI is a private company, so its shares have no public market price. Caplight tracks illumicell AI's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.

How much is illumicell AI worth (valuation)?

Valuation information for illumicell AI is not publicly available.

Can I buy illumicell AI stock?

illumicell AI shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.

When was illumicell AI's last funding round?

illumicell AI's most recent funding round was VC Round on June 19, 2026.

Who are the main investors in illumicell AI?

Key investors in illumicell AI include Harvard Innovation Labs, Techstars, KOFA Healthcare, Creative Destruction Lab, MedTech Syndicates.

Will illumicell AI IPO soon?

No public IPO plans have been announced for illumicell AI.

How can I track illumicell AI secondary market activity?

Caplight tracks bids, offers, and trades in illumicell AI's shares on secondary markets.

Firmographic Details

HeadquartersUnited States
Employee Range20
Year Founded2023
Last FundingJun 19, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?